Disappointing top-line revenues and terrible 2013 guidance of flat sales. Analyst estimates have to come down for 2013 product sales.
Management reiterates one day in the future it will be a big drug. That one day ain't gonne happen anytime soon.
Paladin: Yes, I did hear the rather sudden switch from "billion" to "multi-billion," which I believe was uttered twice near the end. Siegall has gotten better at these things, but he still has a tendency to become tongue tied or lost in the weeds. He needs more consistent clarity, a more linear approach. Also, talking about getting lost in the weeds, a new side effect of Adcetris might be induced coma from listening to that marketing guy - yes, I agree with you there, too.
Biotech: I was thinking the same thing -- given the time frames involved in this market sector, we are looking at another looooonnng wait before Adcetris revenues grow robustly and/or new products come on line. So, we're back to being very long-term investors with only one real hope for swift pps appreciation -- the takeover, which I still think is inevitable, maybe tomorrow, maybe a year from tomorrow, but one day fersure, and at a very high premium.